Imugene (ASX:IMU) will raise AU$46 million via the issue of notes and warrants to investor CVI Investments, according to a Monday filing with the Australian bourse.
The offer comprises AU$20 million in senior unsecured zero-coupon convertible notes maturing in five years and AU$26 million worth of five-year unlisted warrants exercisable at AU$0.0494, the filing said.
If the investor decides to convert the bonds into shares, its conversion value will be 25% above the immuno-oncology firm's closing price on Dec. 20, per the filing.
Proceeds will be used to advance the company's azer-cel, onCARlytics, and Vaxinia trials, as per the filing.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。